NCT06589726View on ClinicalTrials.gov

A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions
Healthy
Interventions
DRUG

Placebo

Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.

DRUG

Moxifloxacin

Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.

DRUG

Enpatoran low dose

Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.

DRUG

Enpatoran high dose

Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.

Trial Locations (1)

Unknown

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT06589726 - A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants | Biotech Hunter | Biotech Hunter